10 Best Diabetes Stocks To Buy Under $10

7. SAB Biotherapeutics, Inc. (NASDAQ:SABS)

Share Price as of the Close of December 26: $4.18

SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company specializing in immunotherapy through its proprietary DiversitAb platform, which produces fully human, high-potency polyclonal antibodies without relying on human donors. The company’s lead asset, SAB-142, targets Type 1 Diabetes (T1D) as a disease-modifying therapy designed to delay the onset and progression of the disease, offering a potential breakthrough over traditional insulin therapies.

The platform’s ability to quickly produce targeted therapies positions SAB Biotherapeutics, Inc. (NASDAQ:SABS) as a leader in multiple therapeutic areas, including infectious diseases and autoimmune disorders. With strong partnerships, government funding, and an innovative approach, the company is poised to address unmet needs in T1D and other diseases, making it an attractive investment opportunity.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) is gaining attention as a top diabetes stock under $10 which was driven by its innovative lead asset, SAB-142, a disease-modifying therapy for Type 1 Diabetes (T1D). SAB-142 has completed Phase 1 enrollment with no serum sickness observed, positioning the company for a Phase 2 study in 2025.

In Q3 2024, the corporation reported a cash position of $30.4 million, R&D expenses of $7.8 million, G&A expenses of $3.5 million, and a net loss of $10.3 million, reflecting increased investment in its pipeline. SAB Biotherapeutics, Inc. (NASDAQ:SABS) presented its clinical progress at the European Association for the Study of Diabetes meeting, with topline Phase 1 data expected by the end of 2024, potentially driving further momentum. Analysts hold a consensus Strong Buy rating on the stock.